Renal tubulointerstitial expansion is associated with endothelial dysfunction and inflammation in type 1 diabetes

References

• Gilbert R. E., Cooper M. E. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?. Kidney Int 1999; 56: 1627–37
   PubMed Web of Science ®Google Scholar
• Wolf G., Ziyadeh F. N. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999; 56: 393–405
   PubMed Web of Science ®Google Scholar
• Osterby R., Bangstad H. J., Rudberg S. Follow‐up study of glomerular dimensions and cortical interstitium in microalbuminuric type 1 diabetic patients with or without antihypertensive treatment. Nephrol Dial Transplant 2000; 15: 1609–16
   PubMed Web of Science ®Google Scholar
• Pecoits‐Filho R., Heimburger O., Barany P., Suliman M., Fehrman‐Ekholm I., Lindholm B., Stenvinkel P. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003; 41: 1212–18
   PubMed Web of Science ®Google Scholar
• Navarro J. F., Mora C. Role of inflammation in diabetic complications. Nephrol Dial Transpl 2005; 20: 2601–4
   PubMed Web of Science ®Google Scholar
• Bangstad H. J., Osterby R., Dahl‐Jorgensen K., Berg K. J., Hartmann A., Hanssen K. F. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 1994; 37: 483–90
   PubMedGoogle Scholar
• Bangstad H. J., Osterby R., Rudberg S., Hartmann A., Brabrand K., Hanssen K. F. Kidney function and glomerulopathy over 8 years in young patients with Type I (insulin‐dependent) diabetes mellitus and microalbuminuria. Diabetologia 2002; 45: 253–61
   PubMedGoogle Scholar
• Eid H. M., Eritsland J., Larsen J., Arnesen H., Seljeflot I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003; 166: 279–84
   PubMed Web of Science ®Google Scholar
• Bangstad H. J., Osterby R., Dahl‐Jorgensen K., Berg K. J., Hartmann A., Nyberg G., et al. Early glomerulopathy is present in young, type 1 (insulin‐dependent) diabetic patients with microalbuminuria. Diabetologia 1993; 36: 523–9
   PubMedGoogle Scholar
• Lane P. H., Steffes M. W., Fioretto P., Mauer S. M. Renal interstitial expansion in insulin‐dependent diabetes mellitus. Kidney Int 1993; 43: 661–7
   PubMed Web of Science ®Google Scholar
• Drummond K., Mauer M. The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 2002; 51: 1580–7
   PubMed Web of Science ®Google Scholar
• Ma L. J., Yang H., Gaspert A., Gaspert A., Carlesso G., Barty M. M., et al. Transforming growth factor‐beta‐dependent and ‐independent pathways of induction of tubulointerstitial fibrosis in beta6(–/–) mice. Am J Pathol 2003; 163: 1261–73
   PubMed Web of Science ®Google Scholar
• Fogo A. B. Progression versus regression of chronic kidney disease. Nephrol Dial Transpl 2006; 21: 281–4
   PubMedGoogle Scholar
• Eddy A. A., Fogo A. B. Plasminogen activator inhibitor‐1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006; 17: 2999–3012
   PubMed Web of Science ®Google Scholar
• Seljeflot I., Larsen J. R., Dahl‐Jorgensen K., Hanssen K. F., Arnesen H. Fibrinolytic activity is highly influenced by long‐term glycemic control in Type 1 diabetic patients. J Thromb Haemost 2006; 4: 686–8
   PubMedGoogle Scholar
• Ziyadeh F. N. Mediators of diabetic renal disease: the case for tgf‐Beta as the major mediator. J Am Soc Nephrol 2004; 15 Suppl 1: S55–7
   PubMed Web of Science ®Google Scholar
• Eddy A. A. Plasminogen activator inhibitor‐1 and the kidney. Am J Physiol Renal Physiol 2002; 283: F209–20
   PubMed Web of Science ®Google Scholar
• Fogo A. B. Renal fibrosis: not just PAI‐1 in the sky. J Clin Invest 2003; 112: 326–8
   PubMed Web of Science ®Google Scholar
• Fliser D., Kronenberg F., Kielstein J. T., Morath C., Bode‐Boger S. M., Haller H., et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16: 2456–61
   PubMed Web of Science ®Google Scholar
• Tarnow L., Hovind P., Teerlink T., Stehouwer C. D., Parving H. H. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004; 27: 765–9
   PubMed Web of Science ®Google Scholar
• Kielstein J. T., Boger R. H., Bode‐Boger S. M., Frölich J. C., Haller H., Ritz E., et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170–6
   PubMed Web of Science ®Google Scholar
• Altinova A. E., Arslan M., Sepici‐Dincel A., Akturk M., Altan N., Toruner F. B. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metab 2007; 92: 1881–5
   PubMed Web of Science ®Google Scholar
• Chan N. N., Chan J. C. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?. Diabetologia 2002; 45: 1609–16
   PubMed Web of Science ®Google Scholar
• Glowinska B., Urban M., Peczynska J., Florys B. Soluble adhesion molecules (sICAM‐1, sVCAM‐1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes. Metabolism 2005; 54: 1020–6
   PubMed Web of Science ®Google Scholar
• Clausen P., Jacobsen P., Rossing K., Jensen J. S., Parving H. H., Feldt‐Rasmussen B. Plasma concentrations of VCAM‐1 and ICAM‐1 are elevated in patients with Type 1 diabetes mellitus with microalbuminuria and overt nephropathy. Diabetes Med 2000; 17: 644–9
   PubMed Web of Science ®Google Scholar
• Navarro J. F., Milena F. J., Mora C., Leon C., Claverie F., Flores C., et al. Tumor necrosis factor‐alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin‐converting enzyme inhibition. Kidney Int 2005; 68: S98–102
   Google Scholar
• Mauer S. M., Steffes M. W., Ellis E. N., Sutherland D. E., Brown D. M., Goetz F. C. Structural–functional relationships in diabetic nephropathy. J Clin Invest 1984; 74: 1143–55
   PubMed Web of Science ®Google Scholar
• Fogo A. B. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol 2007; 22: 2011–22
   PubMed Web of Science ®Google Scholar
• Taft J. L., Nolan C. J., Yeung S. P., Hewitson T. D., Martin F. I. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994; 43: 1046–51
   PubMed Web of Science ®Google Scholar